Literature DB >> 9233418

Incorporation of ultrasonic imaging in an optically coupled frameless stereotactic system.

H Hirschberg1, G Unsgaard.   

Abstract

Frameless stereotactic interactive tracking systems relate a point in the surgical field to a corresponding point on the patients MR or CT scans in multiple planes. A basic weakness with these systems is that they cannot compensate for movement of target points due to brain shift caused by CSF drainage or lesion removal. Real time images can be obtained using ultrasonic techniques but the poor quality and definition and the ill-defined scan plane make interpretation difficult and reduce the usefulness of this modality. The authors have combined these two modalities by mounting light emitting diodes (LEDs) on the ultrasonic probe, thus allowing a "virtual tip" to be developed in the centre of the ultrasonic beam, and tracked via an optically coupled frameless stereotactic system (Radionics, OTS). This has allowed a direct correlation between pre-operative MR and the per-operative ultrasonic images using reformatted MR images. Ultrasound images are obtained through a separate skull opening and the image plane is determined by the position of the virtual tip. The ultrasonic and MR images are presented side by side for visual comparison. Minimally invasive tumour resection or haematoma removal could be carried out under ultrasonic guidance with direct interactive relation to the preoperative MR scans. Alternatively interactive image directed surgical procedures can be up-dated in real time by dynamic ultrasonic images taken in clearly defined scan planes.

Entities:  

Mesh:

Year:  1997        PMID: 9233418     DOI: 10.1007/978-3-7091-6513-3_14

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  1 in total

Review 1.  Neuronavigation and surgery of intracerebral tumours.

Authors:  P W A Willems; J W Berkelbach van der Sprenkel; C A F Tulleken; M A Viergever; M J B Taphoorn
Journal:  J Neurol       Date:  2006-09-20       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.